Noxopharm receives $1.4 million R&D tax incentive rebate
Noxopharm Limited (ASX:NOX) has received a rebate of $1,422,471 under the Australian Government’s Research and Development Tax Incentive scheme, covering expenditure during FY 2026. The company announced the receipt on 12 November 2026.
The rebate will support the upcoming SOF-SKN™ extension study in patients with cutaneous lupus erythematosus (CLE), as well as the Sofra™ technology platform more generally. The funds are earmarked for two uses:
The extension study is structured as a 15-patient Melbourne study with a 14-day daily topical dosing regimen, following completion of the HERACLES Phase I trial in healthy volunteers.
- The SOF-SKN™ extension study in patients with CLE
- The broader Sofra™ technology platform
The study is designed to assess the safety and tolerability of SOF-SKN in patients with CLE, also known as skin lupus, and to generate initial signals of clinical efficacy.
When big ASX news breaks, our subscribers know first
Why cutaneous lupus is a target market
The global CLE treatment market was valued at US$5.4 billion in 2024. Lupus is an autoimmune disease that can affect different organs, and CLE is a sub-type that manifests in the skin. There are currently no therapies specifically approved for treating CLE.
There is also an option to expand SOF-SKN into adjacent inflammatory autoimmune skin disease, including:
- Psoriasis
- Dermatomyositis
- Rosacea
The broader Sofra platform is also being explored across other diseases associated with immune-system dysregulation, including cancer.
Investors exploring Sofra beyond skin disease can read our full explainer on CSL’s Sofra mRNA vaccine data, which covers the independent results presented at a major influenza conference and what they mean for partnering prospects.
Want Alerts Like This on the Biotech Stocks You Follow?
StockWire X Market Intelligence scores every announcement in our coverage for how significant it’s likely to be for investors, and which way it points, then alerts you on the stocks you follow. The first 1,000 founding members lock in 50% off for life: A$247 a year instead of the standard A$495. Join the founding waitlist today.